KMT2A and acute lymphoblastic leukemia: In fact, the fold-change in EFS between the combination treatment and control groups (EFStreated/EFScontrol = 3.25, Table 1) is comparable to that produced by an ALL induction therapy-based regimen, VXL (vincristine, dexamethasone, and L-asparaginase) (EFStreated/EFScontrol = 3.18) or the combination of CBL0137 and cyclophosphamide (EFStreated/EFScontrol = 3.35), which we have tested previously in the same MLL-6 PDX model (5).